Making Sense of the Science of WM sets out a framework for patients to understand the basic genetic concepts behind the mutations that are important in WM, to appreciate the ways in which these mutations impact the signaling systems that control the behavior of WM cells, and to recognize how these mutations are changing the landscape of therapies for WM.

Steven P. Treon, MD, PhD, of Dana-Farber Cancer Institute, discusses Bruton’s tyrosine kinase (BTK), which is activated during severe COVID-19 infection. Patients with the coronavirus and chronic lymphocytic leukemia who remained on the BTK inhibitor ibrutinib had a mild disease course, with decreased C-reactive protein and improved oxygenation. Clinical trials to validate the role of BTK inhibitors in treating COVID-19–related pulmonary distress are now underway.

Dr. Steven Treon delivered this on-line lecture on August 5, 2020 for the benefit of the WMFC Toronto Support Group. It is our privilige to share it with the entire WM community.  It focuses on the role of BTK Inhibitors in the treatment of Waldenstrom's Macroglobulinemia, and the advances being made based on the latest research.

The International Waldenstrom's Macroglobulinemia Foundation invites you to join us for the first installment in our 2020 IWMF Global Educational Webinar series.

When Peter DeNardis was diagnosed with Waldenstrom macroglobulinema (WM) 17 years ago, all he knew was that he had an incurable cancer. He had never heard of this rare type of non-Hodgkin lymphoma. A married father of three in his early 40s, DeNardis worried about how his illness would impact his family. How would his passing affect them emotionally and financially?

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time.

As most of you know, the 2020 IWMF Educational Forum will be virtual/online and is coming soon (August 27-28) - see agenda and registration details at: https://www.iwmf.com/news-and-events/iwmf-educational-forum.

The WMFC (the Canadian affiliate of the IWMF) was proud to have Dr. Zachary Hunter of the Dana-Farber Cancer Institute join the Atlantic Canada WM Support Group for a recent virtual meeting. Dr Hunter described the latest research into Waldenstrom’s macroglobulinemia. After his talk, he took questions from the participants and described the latest research project he is taking on with the financial backing of the WMFC, IWMF, LLS and the Leukemia Foundation of Australia.

Peter DeNardis was diagnosed with Waldenstrom macroglobulinemia in 2003 and is a board member for the International Waldenstrom’s Macroglobulinemia Foundation (IWMF). He shares his personal story of living with Waldenstrom and explains how new treatments for Waldenstrom macroglobulinemia are evolving. He also shares why patients who have this rare cancer can finally be hopeful about the future.

Dana Farber/Brigham and Women’s Cancer Center has been recognized as a Best Hospital for 2020-21 by U.S. News & World Report.  For the 20th straight year, Dana-Farber/Brigham and Women’s Cancer Center is ranked as the best hospital for cancer care in New England and is ranked #6 in the nation this year.